
    
      Hospitalized men with COVID-19 who meet the eligibility criteria will be informed about study
      and the potential risks. All the patients giving written informed consent will be randomized
      in 1:1 ratio to progesterone (100 mg SQ twice daily) plus standard of care or standard of
      care alone.
    
  